Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zai Lab Ltd.

www.zailaboratory.com

Latest From Zai Lab Ltd.

Breaking Away From Betta, Jacobio Raises China Oncology Development Bar

Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.

StartUps and SMEs Cancer

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Clinical Trials Cancer

Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • ZAI Laboratory Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Zai Lab Ltd.
  • Senior Management
  • Samantha Du, PhD, Chmn. & CEO
    Billy Cho, CFO
    Jonathan Wang, SVP, Head, Bus. Dev.
    William Liang, Chief Commercial Officer
    Tao Fu, Pres. & COO
  • Contact Info
  • Zai Lab Ltd.
    Phone: 21 6163 2588
    4560 Jinke Rd., Jinchuang Plaza Bldg. 1
    Zhangjiang Pk.
    Pudong, Shanghai, 201210
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register